Ad
related to: von willebrand' s treatment
Search results
Results from the WOW.Com Content Network
Von Willebrand disease (VWD) is the most common hereditary blood-clotting disorder in humans. An acquired form can sometimes result from other medical conditions. [ 1 ] It arises from a deficiency in the quality or quantity of von Willebrand factor (VWF), a multimeric protein that is required for platelet adhesion .
The following side effects may occur during treatment with vonicog alfa: hypersensitivity (allergic) reactions, thromboembolic events (problems due to the formation of blood clots in the blood vessels), development of inhibitors (antibodies) against von Willebrand factor, causing the medicine to stop working and resulting in a loss of bleeding control. [5]
In addition, desmopressin (DDAVP) is known to be effective in people with von Willebrand's disease, [17] [18] including people with valvular heart disease. [19] [20] Desmopressin stimulates release of von Willebrand factor from blood vessel endothelial cells by acting on the V2 receptor, which leads to decreased breakdown of Factor VIII.
Type 1 von Willebrand Disease in dogs. Type 1 von Willebrand Disease is the most common type, and also the mildest. It occurs when dogs have a mild deficiency in all the proteins making up their ...
Desmopressin (DDAVP) is usually the first line treatment for mild to moderate type 1 von Willebrand disease. [1] It is not recommended in severe disease or in those with abnormal factor VIII. [1] Usefulness in type 2A, 2M, or 2N von Willebrand disease is variable. [1] Generally not recommended in 2B and type 3 von Willebrand disease. [1]
Von Willebrand factor (VWF) (German: [fɔn ˈvɪləbʁant]) is a blood glycoprotein that promotes hemostasis, specifically, platelet adhesion.It is deficient and/or defective in von Willebrand disease and is involved in many other diseases, including thrombotic thrombocytopenic purpura, Heyde's syndrome, and possibly hemolytic–uremic syndrome. [5]
[13] [14] Certain preparations may also be used in those with von Willebrand's disease. [14] It is given by slow injection into a vein. [13] Side effects include skin flushing, shortness of breath, fever, and red blood cell breakdown. [13] [14] Allergic reactions including anaphylaxis may occur. [14]
On 30 August 2018, it was approved in the European Union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression". [10] It is an anti-von Willebrand factor humanized immunoglobulin. [11]
Ad
related to: von willebrand' s treatment